Paying for Remodulin

Remodulin Co-Pay Assistance Card

For patients with commercial or private insurance plans, we offer a co-pay card to help patients cover some of their out-of-pocket expenses.

Most eligible patients pay as little as a $0.00 co-pay per month for Remodulin. The Remodulin Co-Pay Assistance Program will automatically pay the difference up to the annual maximum benefit.*

Terms and Conditions

*Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.

Patient Assistance Program (PAP)

United Therapeutics offers a free medication program for uninsured and underinsured patients who meet eligibility requirements.

Call ASSIST at 1-877-864-8437 to find out if your patient qualifies for financial support.

Patients with commercial and/or employer funded insurance plans requiring them to apply to United Therapeutics ASSIST Patient Assistance Program as a prerequisite to or requirement for coverage of United Therapeutics Corporation products, commonly known as alternate funding programs (also referred to as specialty carve-outs, patient advocacy programs, or specialty networks) are not eligible for United Therapeutics ASSIST Patient Assistance Program.

Questions?

You can call ASSIST at 1-877-864-8437, Monday - Friday, 8:30am to 7:00pm ET or email ASSIST at assist@unither.com.

Important Reminder

Please remind your patients to keep the Specialty Pharmacy informed about their current insurance status.

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

Important Safety Information for Remodulin

Warnings and Precautions

Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.

Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.

Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.

Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.

Remodulin inhibits platelet aggregation and increases the risk of bleeding.

Adverse Reactions

In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%) jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).

Drug Interactions

Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

Specific Populations

In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.

Safety and effectiveness of Remodulin in pediatric patients have not been established.

It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.

There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

For additional information please see Full Prescribing Information or call Customer Service at 1-877-UNITHER (1-877-864-8437)